Search

Author/Creator Siliquini, Niccolò

2. Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real‐life experience in a tertiary referral centre. (27th May 2021)

Authors:
Gallo, Giuseppe; Rostagno, Elisabetta; Siliquini, Niccolò; Stroppiana, Elena; Verrone, Anna; Ortoncelli, Michela; Quaglino, Pietro; Dapavo, Paolo; Ribero, Simone
Journal:
Australasian journal of dermatology
Issue:
Volume 62:Number 3(2021)
Page Start:
e431
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. (19th May 2022)

Authors:
Dapavo, Paolo; Siliquini, Niccolò; Mastorino, Luca; Avallone, Gianluca; Merli, Martina; Agostini, Andrea; Cariti, Caterina; Viola, Riccardo; Stroppiana, Elena; Verrone, Anna; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone
Journal:
Journal of dermatological treatment
Issue:
Volume 33:Number 4(2022)
Page Start:
2352
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population. (1st August 2022)

Authors:
Mastorino, Luca; Roccuzzo, Gabriele; Dapavo, Paolo; Siliquini, Niccolò; Avallone, Gianluca; Rubatto, Marco; Merli, Martina; Agostini, Andrea; Ribero, Simone; Quaglino, Pietro
Journal:
British journal of dermatology
Issue:
Volume 187:Number 2(2022)
Page Start:
263
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population. (24th May 2022)

Authors:
Mastorino, Luca; Roccuzzo, Gabriele; Dapavo, Paolo; Siliquini, Niccolò; Avallone, Gianluca; Rubatto, Marco; Merli, Martina; Agostini, Andrea; Ribero, Simone; Quaglino, Pietro
Journal:
British journal of dermatology
Issue:
Volume 187:Number 2(2022)
Page Start:
263
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Issue 5 (28th February 2022)

Authors:
Mastorino, Luca; Susca, Sara; Megna, Matteo; Siliquini, Niccolò; Quaglino, Pietro; Ortoncelli, Michela; Avallone, Gianluca; Rubatto, Marco; Fabbrocini, Gabriella; Dapavo, Paolo; Ribero, Simone
Journal:
Dermatologic therapy
Issue:
Volume 35:Issue 5(2022)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗